Pilot study: The retina as a potential window to visualize neuropathology in Alzheimer's disease.

Completed

Conditions: Alzheimer's disease
dementia
10029305

Registration Number: NL-OMON42260

Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

- Study cases: Patients with early onset (<70 years) AD according to the NINCDS/ADRDA criteria. The patients need to be fully capacitated and able to give informed consent, with a minimum MMSE-score of 17/30 (according to other AD-protocols);- Controls: patients with subjective memory complaints visiting the Alzheimer center, without diagnosis of AD or other neurodegenerative disease.

Exclusion Criteria

- Patients with neuro-opthalmological conditions, which may interfere with the OCT and/or FAF data will be excluded (Table 2, Tewarie et al., 2012).
- Patients with progressive dementia, with an MMSE below 17/30 and/or incapacitated and not capable to give informed consent
- Patients with a narrow anterior angle of the eye and/or increased intra-ocular pressure. These patients have a contra-indication to use mydriatic agents.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Methods: We will conduct an overal examination of the eye, including vision,<br /><br>eye pressure and fundusphotography. With the use of FDT visual field<br /><br>examination and HRT scan of the optic disc, we aim to exclude glaucoma.<br /><br>Moreover, we conduct OCT and FAF measurements. Prior to measurements with OCT<br /><br>and FAF, pupil dilatation will be performed using tropicamide 0.5%. In total,<br /><br>the examinations will take around 45 minutes.<br /><br><br /><br>Primary study parameters/outcome of the study:<br /><br>(1) Thickness of retina, macula and/or optic disc with OCT<br /><br>(2) Visualization of amyloid plaques in AD with FAF</p><br>

Secondary Outcome Measures